

## RD General Agenda Topics – March 1, 2021

### Briefings for Michal

- PRIA/registration overview 2/23<sup>rd</sup> (complete)
- Dicamba 2/18<sup>th</sup> (complete)
- Sulfoxaflor 3/4<sup>th</sup> (pre-meeting with Ed 3/1<sup>st</sup>)

### New Active Ingredients (include original PRIA date)

- Tetraniliprole – PD signed. PRIA date **3/31/21** (Original PRIA date 3/27/19) (IVB3). FRN is signed. Significant comments on the PD (over 7000) including significant issues raised by pollinator stewardship council.
- Broflanilide – completed!
- Fluindapyr – PD signed. PRIA Date **3/5/21** (Original PRIA date 5/29/20) (FB)
- Trifludimoxazin – PD signed. PRIA date **4/21/21** (Original PRIA date 10/16/2020) (FHB)
- Picarbutrazox – PD signed. PRIA date **3/15/21** (Original PRIA date 10/16/2020) (FHB)
  - Package (FRN, FD, RTC, one pager) cleared OPP-IO; **waiting for FRN to post**
- Fluxametamide (import tolerance only, residue pilot) – signed **PRIA date 3/2/21** (Original PRIA due 2/1) – completed!
- L-Glufosinate Ammonium – Risk Assessment phase. PRIA date 10/12/2021. **ESA issue. Any feedback?**

### Other Chemical Actions

- Dicamba (Dan K)
  - **Fexapan (Corteva) – 100% repack; approved**
  - **24 (c)s –**
    - GA has resubmitted – no cutoff date, reduced buffer distances
    - TN and NC submissions – both asking for soybean cutoff date of 7/30<sup>th</sup> (to match cotton)
    - **Notice of intent to disapprove (with Ed); next steps?**
- Antibiotics – will need to brief the new team (Cynthia)
  - Oxytet – cherry; public process (perhaps not needed)
  - Consultation with partners – Kasugamycin (almond, peach, apricot)
- Cyclaniliprole/flonicamid – first residential use; public process; teams are addressing RD IO comments; should come to OPP-IO soon; **do we do an OPP update to announce comment period?**
- Seresto – pet collar with high rate of incidents (death and neuro); planning a briefing

### Other Actions - AA-Level/OD/High Visibility Items

- FDA/EPA jurisdiction – follow up briefing for Ed 3/10<sup>th</sup> – **anything needed in particular?**
- COVID-19 Activities – Sect 18s –

- SW2 – other use sites being evaluated
- Grignard – other states
- Kraton – bi-weekly meetings
- Ionopure Air

## Ex. 5 Deliberative Process (DP)

sharing it with their supervisors

### Business/process/technology

- ISB – FEP/21-day backlog:
  - backlog addressed by end of April; RD SWAT team addressing newer receipts
  - Michal feedback on expediting all covid actions?
- eCSF/OPPEL – OPP priority?

### Speaking Engagements –

- Gold Seal Updates for CLA/RISE Workgroup (Catherine Aubee, Shanta Adeeb, Marion Johnson, ITRMD participant), (date TBD) <<will follow up to see if this is still needed
- AMCA meeting (Virna Stillwaugh)

## Ex. 5 Deliberative Process (DP)

- CITAB/Acute tox team leader – moving forward with Julie Breeden-Alemi
- CITAB/Inerts team leader – re-advertising
- IVB3/HB – talent hub (Meredith and Dan retirements)
- FHB/PM position – will need to advertise separately
- FTE discussion (any updates?)
- Developing PMF process proposal with OPP Recruitment and Hiring Workgroup